NCT05137067View on ClinicalTrials.gov

A Novel Approach for Alleviating the Side Effects of Chemotherapeutic Agents.

PHASE2CompletedINTERVENTIONAL
Enrollment

90

Participants

Timeline

Start Date

January 20, 2021

Primary Completion Date

October 18, 2022

Study Completion Date

May 25, 2023

Conditions
Breast CancerLung CancerProstate Cancer
Interventions
DIETARY_SUPPLEMENT

Chemotherapeutic agent A(Docetaxel),B(Cisplatin) or C(Docetaxel) plus Dietary Supplement (RaproCell)

Chemotherapeutic side effect elimination without adversely effecting the Chemotherapeutic agent drug.

DRUG

Chemotherapeutic agent A(Docetaxel),B(Cisplatin) or C(Docetaxel) plus placebo

Placebo

DRUG

Chemotherapeutic agent A(Docetaxel),B(Cisplatin) or C(Docetaxel).

Chemotherapeutic agent A(Docetaxel),B(Cisplatin) or C(Docetaxel).

Trial Locations (1)

84117

Optimal Health Research, Salt Lake City

All Listed Sponsors
lead

Optimal Health Research

OTHER

NCT05137067 - A Novel Approach for Alleviating the Side Effects of Chemotherapeutic Agents. | Biotech Hunter | Biotech Hunter